Compare UAA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAA | MESO |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | UAA | MESO |
|---|---|---|
| Price | $4.33 | $17.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 2 |
| Target Price | $6.34 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 8.1M | 211.8K |
| Earning Date | 11-06-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,049,070,000.00 | $17,198,000.00 |
| Revenue This Year | N/A | $465.44 |
| Revenue Next Year | $1.54 | $75.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $4.13 | $9.61 |
| 52 Week High | $10.28 | $22.00 |
| Indicator | UAA | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 56.73 |
| Support Level | $4.29 | $16.43 |
| Resistance Level | $4.55 | $17.65 |
| Average True Range (ATR) | 0.14 | 0.59 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 14.77 | 56.31 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.